Josep M. Cruzado

Josep M. Cruzado is presented as a nephrologist and investigator working at the intersection of hepatitis C virus infection, renal transplantation, and extrahepatic kidney disease. His decisive contribution is the argument that the timing of antiviral treatment matters: clearing HCV before transplantation can preserve the future renal allograft by reducing the risk of HCV-related glomerulonephritis, while treatment begun after transplantation may endanger the graft through acute rejection. His work therefore joins virologic clearance to the practical governance of transplant candidates, waiting lists, immunosuppression, and scarce donor organs.

Identity and Institutional Setting

Josep M. Cruzado is identified as a member of the Nephrology Department at Hospital Universitary de Bellvitge, University of Barcelona, and IDIBELL, in L’Hospitalet de Llobregat, Barcelona, Spain. The volume places him among clinicians studying the renal consequences of HCV in transplant recipients rather than treating the infection as solely hepatic. In the chapter devoted to extrahepatic complications after renal transplantation, he appears alongside Oriol Bestard and Josep M. Grinyó as a co-author, with the chapter specifically examining diabetes and glomerulonephritis in the renal allograft recipient.

His professional identity is also established through a cited study on pretransplant interferon. That work is described as demonstrating that pretransplant interferon prevents HCV-associated glomerulonephritis in renal allografts by clearing HCV RNA. The repeated return to this finding makes Cruzado a representative of a prevention-oriented transplant nephrology: the key intervention is not merely to manage a damaged graft, but to remove the viral condition before the graft is exposed to its consequences.

Research on Pretransplant Clearance

Cruzado’s central clinical claim concerns sustained virological response before kidney transplantation. In the evidence reviewed by the volume, a small controlled trial found that wait-listed kidney candidates who achieved SVR before transplantation had a significantly lower incidence of HCV-associated glomerulopathy after transplantation. The finding gives concrete force to the broader recommendation that HCV eradication should, whenever possible, be pursued before the operation rather than deferred until the patient is receiving immunosuppression.

The durability of this strategy is supported by evidence that HCV RNA clearance after alpha-interferon therapy in dialysis patients can persist after renal transplantation. The volume reports that, among patients who achieved SVR before transplantation, the probability of remaining HCV-RNA-negative was 95% at 48 months after transplantation. Cruzado’s work adds a second dimension to that virologic result: clearance is not only a laboratory endpoint but also a means of preventing a new immune-complex disease in the renal allograft.

The preventive logic is especially important because HCV infection is associated with lower patient and graft survival in renal transplantation. The increased mortality risk is linked principally to cardiovascular disease, insulin resistance, and new-onset diabetes after transplantation rather than simply to progression of HCV-related liver disease. Graft survival is further threatened by de novo HCV-related glomerulonephritis and by the higher risk of chronic humoral rejection. Cruzado’s research connects these outcomes to a modifiable point in the clinical sequence: treatment before implantation may reduce complications that become difficult or dangerous to treat once the kidney is functioning under immunosuppression.

Glomerulonephritis in the Renal Allograft

The chapter associated with Cruzado describes HCV-related glomerulonephritis as a major risk to the transplanted kidney. HCV remains an independent predictor of graft outcome, even in protocol-biopsy studies. Although some investigators attribute part of the damage to the heightened immunological risk of many HCV-infected recipients, the evidence also supports a direct relationship between HCV, autoimmunity, and glomerular disease. HCV-infected recipients may develop glomerulitis and transplant glomerulopathy, conditions associated with anti-HLA antibodies and antibody-mediated rejection.

Cruzado’s account also acknowledges that the mechanism is not reducible to one pathway. HCV infection has been associated with thrombotic microangiopathy in renal allografts in the presence of pretransplant anticardiolipin antibodies, although this complication is seldom encountered in HCV-infected transplant recipients. For membranoproliferative glomerulonephritis, the proposed mechanism involves the inflammatory behavior of the allograft itself. Mesangial cells may express Toll-like receptor 3 under inflammatory stimulation; HCV double-strand RNA can bind to that receptor, amplifying local cytokine and chemokine production and promoting mononuclear-cell recruitment and mesangial apoptosis.

This mechanistic emphasis strengthens Cruzado’s preventive argument. Even low levels of circulating immune complexes do not exclude the development of MPGN, because the transplanted kidney may provide a particularly responsive inflammatory environment. The allograft is therefore not a passive recipient of systemic disease. It can become a site where viral material, innate immune signaling, and transplant-specific vulnerability converge.

Treatment, Risk, and Clinical Judgment

Cruzado’s work is cautious about treatment after transplantation. Management of de novo HCV-related glomerulonephritis is described as mainly symptomatic, and there is no clear evidence that a particular immunosuppressant is either specifically harmful or protective in this setting. Interferon is generally avoided in renal allograft recipients because of its association with acute rejection and graft loss. Ribavirin has produced some positive experiences, but renal insufficiency can intensify its hemolytic anemia, and ribavirin monotherapy cannot produce sustained virological response.

Rituximab has been reported as successful in some cases of HCV-related MPGN. In the experience associated with Cruzado’s group, rituximab treatment was accompanied by disappearance of cryoglobulinemia and glomerular subendothelial immune deposits. The treatment nevertheless carries a clinical paradox: it may produce overimmunosuppression and may increase viral replication. The apparent improvement in the kidney must therefore be weighed against the possibility of weakening host defenses and intensifying the infection that helped generate the renal lesion.

These risks explain why the volume presents prevention as preferable to rescue therapy. Treatment of HCV-infected renal transplant candidates with interferon, alone or with ribavirin, can produce SVR in at least half of patients, and the viral response is usually maintained after transplantation. Cruzado’s contribution turns that general therapeutic result into a transplant-specific principle: HCV clearance before transplantation avoids the development of HCV-related glomerular lesions after transplantation.

Role in Transplant Policy and Significance

The implications of Cruzado’s work extend beyond individual treatment decisions. Candidates with active HCV infection require screening, staging of liver disease, and continuing surveillance while they remain on the waiting list. Patients with positive nucleic acid testing may be placed on hold and referred for hepatological evaluation. Those who achieve SVR require continued annual testing to confirm that the response remains durable, while patients who remain viremic require repeated assessment for progression of liver disease. The clinical pathway thus turns virologic status into a determinant of eligibility, timing, and transplant strategy.

At the same time, Cruzado’s prevention model operates within the scarcity of donor kidneys. HCV-positive donor kidneys are often discarded, even though HCV-infected end-stage renal disease patients who are not candidates for, refuse, fail, or withdraw from interferon-based therapy may benefit more from transplantation than from remaining on dialysis. In that setting, HCV-positive donor kidneys may be offered to HCV-positive recipients to shorten waiting time, although such a policy is incompatible with a strategy requiring pretransplant SVR. The contrast reveals the ethical and clinical tension at the center of the subject: viral eradication may protect a graft, but prolonged treatment and exclusion from the waiting list can also prolong exposure to dialysis.

Cruzado’s narrative role in the volume is therefore both scientific and institutional. He helps shift the question from whether HCV is present to when it is cleared, how its immune consequences are expressed in a transplanted kidney, and which risks should be accepted when treatment, waiting, transplantation, and organ scarcity collide. His work gives the book one of its clearest causal sequences: HCV produces systemic and renal vulnerability; immunosuppression can magnify that vulnerability; pretransplant clearance can interrupt it; and post-transplant treatment may be too hazardous to serve as an equivalent substitute.